Neurocrine Crushes Q2: $2.85 EPS vs $1.34 Consensus, Raises INGREZZA Guidance to $2.85B

summarizeSummary

Neurocrine Biosciences reported Q2 2026 non-GAAP EPS of $2.85, more than doubling the $1.34 consensus, and raised INGREZZA full-year sales guidance to $2.825–$2.875 billion. Total revenue grew 39% to $959 million, driven by strong performance across INGREZZA, CRENESSITY, and newly acquired VYKAT XR.

check_boxKey Events · Earnings and Guidance · NBIX

• Q2 Earnings Massively Beat Consensus

  Non-GAAP diluted EPS of $2.85 versus consensus of $1.34, on total revenue of $959 million (up 39% YoY). GAAP net income was $144 million, or $1.39 per diluted share.

• INGREZZA Guidance Raised

  Full-year 2026 INGREZZA net product sales guidance increased to $2.825–$2.875 billion, up from prior $2.7–$2.8 billion, reflecting 15% Q2 growth to $716 million.

• VYKAT XR Acquisition Performing

  VYKAT XR contributed $54 million in the partial quarter post-acquisition (May 18 close); pro-forma full-quarter sales were $94 million, supporting the $2.9 billion Soleno deal.

• CRENESSITY Sales Surge 247%

  CRENESSITY net product sales reached $184 million in Q2, driven by strong patient demand and approximately 80% reimbursement for dispensed prescriptions.

auto_awesomeAnalysis · NBIX · Life Sciences

A massive Q2 beat underscores the strength of Neurocrine's commercial engine, with non-GAAP EPS of $2.85 far outpacing the $1.34 consensus on the back of 39% revenue growth to $959 million. The flagship tardive dyskinesia therapy, INGREZZA, grew 15% to $716 million, prompting management to lift full-year sales guidance to $2.825–$2.875 billion. Validation of the $2.9 billion Soleno acquisition came from newly acquired VYKAT XR, which delivered $54 million in the partial quarter and pro-forma full-quarter sales of $94 million. Meanwhile, CRENESSITY sales surged 247% to $184 million. Despite the robust top line, cash fell to $482 million from $2.5 billion at year-end, reflecting the Soleno deal and a new $1.0 billion credit facility. A Chief Business Officer promotion signals continued strategic focus. Looking ahead, Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia are expected in 2027, adding long-term optionality. This report fundamentally strengthens the investment thesis — the commercial portfolio is accelerating, the acquisition is performing, and the pipeline is advancing.